← All trials
NCT04471922
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 21, 2019
- Primary completion
- Mar 28, 2019
- Completion date
- Mar 28, 2019
- First posted
- Jul 15, 2020
- Last posted
- Jul 15, 2020
- Enrollment
- 45
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Sihuan Pharmaceutical Holdings Group Ltd.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.